Medical device company IDEXX Laboratories, Inc. (NASDAQ: IDXX) on Monday reported higher revenues and net income for the fourth quarter of 2024.
- Fourth-quarter revenues increased 6% annually to $954.3 million; organic revenue growth was 6%
- Net income attributable to shareholders moved up to $216.1 million in Q4 from $194.5 million a year earlier
- On a per-share basis, fourth-quarter earnings rose to $2.62 from $2.32 in Q4 2023
- For fiscal 2025, the management expects revenues to be in the range of $4.06 billion to $4.17 billion, reflecting a growth of 4-7%
- Full-year organic revenue growth is expected to be between 6% and 9%
- The management is looking for earnings of $11.74 per share to $12.24 per share for FY25, an increase of 10-15% on a reported basis
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Infographic: How Lennar (LEN) performed in Q4 2025
Lennar Corporation (NYSE: LEN) reported total revenues of $9.4 billion for the fourth quarter of 2025, compared to $9.9 billion reported in the same period a year ago. Net earnings
Paychex expected to report higher revenue and earnings for Q2 FY26
Paychex, Inc. (NASDAQ: PAYX), a leading provider of human capital management solutions, is undergoing an AI-driven transformation that enhances both its internal operations and client-facing services. Entering fiscal 2026, the
Signet Jewelers (SIG): A look at the progress made on Grow Brand Love
Shares of Signet Jewelers Limited (NYSE: SIG) fell over 3% on Tuesday. The stock has gained 3% year-to-date. The jewelry retailer delivered strong results for the third quarter of 2026,
